Вы находитесь на странице: 1из 12

MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND

VERSION 13 PUBLISHED APRIL 2018

SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
HIV IN COMBINATION WITH OTHER ANTI-
ABACAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NHS ENGLAND CLINICAL
HIV IN COMBINATION WITH OTHER ANTI-
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
ABACAVIR + LAMIVUDINE + RETROVIRAL DRUGS
DOLUTEGRAVIR (TRIUMEQ®) B06/P/b/AGREED REGIONAL GUIDELINES
HIV IN COMBINATION WITH OTHER ANTI-
ABACAVIR + LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ABALOPARATIDE DRUGS AFFECTING BONE
MALE AND JUVENILE OSTEOPOROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM
NHS ENGLAND CLINICAL
ABATACEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY: E03/P/d; TA NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
373
PAEDIATRIC INDICATIONS (WHERE
ABATACEPT NHS ENGLAND CYTOKINE MODULATORS AS PER ADULT TA'S (TA195, TA280) NICE NICE NICE √
ADULT TA AVAILABLE)
TA259, 387 (SEE ALSO SSC1438)
NICE/NHS ENGLAND POLICY NICE
ABIRATERONE CANCER NHS ENGLAND HORMONE ANTAGONISTS ONLY IN ENZALUTAMIDE NAÏVE SACT √ √
PATIENTS
NHS ENGLAND CLINICAL
ADALIMUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY: E03/P/d; TA NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
373
ADALIMUMAB UVEITIS - ADULTS NHS ENGLAND CYTOKINE MODULATORS TA460 NICE NICE NICE AUDIT √ √

HIGHLY SPECIALISED HIGHLY SPECIALISED


ADALIMUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √
CRITERIA ONLY CRITERIA ONLY
AS PER TA455 OR ADULT TA'S (TA130,
PAEDIATRIC INDICATIONS (OR WHERE
ADALIMUMAB NHS ENGLAND CYTOKINE MODULATORS TA143, TA146, TA187, TA199, TA329, NICE NICE NICE AUDIT √ √
ADULT TA AVAILABLE)
TA392, TA460)
ADALIMUMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS NICE TA 392 NICE NICE NICE AUDIT √ √
VIRAL HEPATITIS (B&C) & NOT ROUTINELY COMMISSIONED
ADEFOVIR HEPATITIS B NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS (CG165)
AFATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA310 NICE NICE SACT √
NOT ROUTINELY COMMISSIONED
AFLIBERCEPT CANCER NHS ENGLAND CANCER EXCLUSION AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ √
(TA307)
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
AGALSIDASE ALFA FABRY'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
AGALSIDASE BETA FABRY'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
ALBUTREPENONACOG ALFA HAEMOPHILIA B
NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √
ALBUTROPIN ADULT ONSET GROWTH HORMONE
GROWTH HORMONE & GROWTH
DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HORMONE RECEPTOR ANTAGONIST

ALDESLEUKIN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
DRUGS AFFECTING THE IMMUNE
ALEMTUZUMAB MULTIPLE SCLEROSIS NHS ENGLAND TA312 NICE NICE NICE AUDIT √ √****
RESPONSE
TRUST GUIDELINES: ISLET
PRE-TRANSPLANT DRUGS AFFECTING THE IMMUNE
ALEMTUZUMAB NHS ENGLAND TRANSPLANTATION (ONLY IF PROVIDED TRUST GUIDELINES TRUST GUIDELINES √
IMMUNOSUPPRESSION RESPONSE
AT ZERO DRUG COST)
DRUGS AFFECTING THE IMMUNE TRUST GUIDELINES: (ONLY IF
ALEMTUZUMAB CLL NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES SACT √
RESPONSE PROVIDED AT ZERO DRUG COST)
HIGHLY SPECIALISED CRITERIA ONLY
HIGHLY SPECIALISED HIGHLY SPECIALISED
ALEMTUZUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS (ONLY IF PROVIDED AT ZERO DRUG HIGHLY SPECIALISED CRITERIA √
CRITERIA ONLY CRITERIA ONLY
COST)
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
ALGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
DRUGS USED IN METABOLIC
ALIPOGENE TIPARVOVEC LIPOPROTEIN LIPASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
VIRAL HEPATITIS (B&C) &
ALISPORIVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
ALPHA MANNOSIDASE DRUGS USED IN METABOLIC
ALPHA MANNOSIDASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RECOMBINANT HUMAN DISORDERS
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NHS ENGLAND CLINICAL
AMBRISENTAN NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION COMMISSIONING POLICY: A11/P/c
HYPERTENSION
NOT ROUTINELY COMMISSIONED
AMIFAMPRIDINE PHOSPHATE LEMS NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND POLICY: 16009/P

AMIKACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

CYSTIC FIBROSIS
AMIKACIN LIPOSOMAL NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

NUMBER OF PATIENTS TREATED


AMPHOTERICIN LIPOSOMAL FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
NHS ENGLAND CLINICAL
ANAKINRA JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: E03/P/d
SPECIALIST AUTOINFLAMMATORY
ANAKINRA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISEASE
ANAKINRA PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CRYOPYRIN ASSOCIATED PERIODIC CRYOPYRIN ASSOCIATED PERIODIC HIGHLY SPECIALISED HIGHLY SPECIALISED
ANAKINRA NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED DATABASE √
SYNDROME SYNDROME SERVICE SPECIFICATION CRITERIA ONLY CRITERIA ONLY
NUMBER OF PATIENTS TREATED
ANIDULAFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
ANTIHAEMOPHILIC FACTOR/VON AS PER BCSH GUIDELINES FOR
NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
WILLEBRAND FACTOR COMPLEX SPECIALISED INDICATIONS

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 1 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL

APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC,


ANTILYMPHOCYTE GLOBULIN NHS ENGLAND BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
ORGAN TRANSPLANT HAEMOLYTIC, AND RENAL ANAEMIAS
ANTIPSEUDOMONAS AERUGINOSA
CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IgY
AS PER BCSH GUIDELINES FOR
ANTITHROMBIN III NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
SPECIALISED INDICATIONS
ANTITHYMOCYTE APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC,
NHS ENGLAND BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
IMMUNOGLOBULIN ORGAN TRANSPLANT HAEMOLYTIC, AND RENAL ANAEMIAS

APREMILAST PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
ARAGAM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
DRUGS USED IN METABOLIC
ASFOTASE ALFA HYPOPHOSPHATASIA NHS ENGLAND HST6 NICE NICE AS PER MAA √ √
DISORDERS
VIRAL HEPATITIS (B&C) &
ASUNAPREVIR + DACLATASVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
DRUGS AFFECTING THE IMMUNE
ATACICEPT SLE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
ATALUREN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NICE HST3 NICE NICE NORTHSTAR DATABASE √ √

HIV IN COMBINATION WITH OTHER ANTI-


ATAZANAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ATAZANAVIR + COBICISTAT HIV IN COMBINATION WITH OTHER ANTI-
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
(EVOTAZ®) RETROVIRAL DRUGS
AVORALSTAT HEREDITARY ANGIOEDEMA NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AXITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA333 (also refer to circular SSC1508) NICE NICE SACT √
AZACITIDINE CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME TA218 NICE NICE SACT √
NHS ENGLAND CLINCAL
AZTREONAM LYSINE CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √*
COMMISSIONING POLICY: A01/P/b
NOT ROUTINELY COMMISSIONED
CYSTIC FIBROSIS (CONTIUOUS
AZTREONAM LYSINE NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND CLINCAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TREATMENT)
COMMISSIONING POLICY: 16001/P
PAEDIATRIC INDICATIONS (WHERE
BARICITINIB NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE)
CORTICOSTEROIDS AND OTHER
BASILIXIMAB RENAL TRANSPLANT NHS ENGLAND TA85 & TA99 NICE NICE √
IMMUNOSUPPRESSANTS
BECLABUVIR HEPATITIS C VIRAL HEPATITIS (B&C) &
NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
NHS ENGLAND CLINICAL
BEDAQUILINE EXTENSIVELY DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: F04/P/a
NHS ENGLAND CLINICAL
BEDAQUILINE MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: F04/P/a
MALIGNANT DISEASE AND
BEGELOMAB GRAFT VERSUS HOST DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IMMUNOSUPPRESSION
DRUGS AFFECTING THE IMMUNE NOT ROUTINELY COMMISSIONED - NICE
BELATACEPT RENAL TRANSPLANT NHS ENGLAND NICE TA IN PROGRESS NICE TA IN PROGRESS NICE TA IN PROGRESS √
RESPONSE TA IN PROGRESS
DRUGS AFFECTING THE IMMUNE
BELIMUMAB SLE NHS ENGLAND NICE TA 397 NICE NICE NICE AUDIT √ √
RESPONSE
BENRALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BERACTANT RESPIRATORY DISTRESS SYNDROME NHS ENGLAND PULMONARY SURFACTANTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED


BETAINE HOMOCYSTINURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
BEVACIZUMAB CANCER CDF ANTINEOPLASTIC DRUGS CDF POLICY CDF CDF SACT √
AS PER NATIONAL PROTOCOL (SEE NF2 AS PER NATIONAL AS PER NATIONAL
BEVACIZUMAB NEUROFIBROMATOSIS NHS ENGLAND ANTINEOPLASTIC DRUGS AS PER NATIONAL PROTOCOL √
SERVICE SPEC) PROTOCOL PROTOCOL
BIMAGRUMAB INCLUSION BODY MYOSITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BIOTIN MULTIPLE SCLEROSIS NHS ENGLAND VITAMINS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SYSTEMIC LUPUS ERYTHEMATOSUS
BLISIBIMOD NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(SLE)
VIRAL HEPATITIS (B&C) &
BOCEPREVIR HEPATITIS C NHS ENGLAND TA253 NICE NICE HEPATITIS C MDS √ √
RESPIRATORY SYNCYTIAL VIRUS
NOT ROUTINELY COMMISSIONED
ORGAN REJECTION POST KIDNEY
BORTEZOMIB NHS ENGLAND ANTINEOPLASTIC DRUGS (NHS ENGLAND CLINICAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRANSPLANT
COMMISSIONING POLICY: A07/P/c)
NHS ENGLAND/ TA129, TA228, TA311, TA 378 NICE NICE
BORTEZOMIB CANCER ANTINEOPLASTIC DRUGS SACT √
CDF CDF POLICY CDF CDF
VASODILATOR ANTIHYPERTENSIVE
NHS ENGLAND CLINICAL
BOSENTAN DIGITAL ULCERS NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: A13/P/b
HYPERTENSION
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NHS ENGLAND CLINICAL
BOSENTAN NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION COMMISSIONING POLICY: A11/P/c
HYPERTENSION
BOSUTINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 401 NICE NICE SACT √
TORSION DYSTONIAS AND OTHER
BOTULINUM TOXIN FOCAL SPASTICITY IN CHILDREN NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √
INVOLUNTARY MOVEMENTS
INTRAVESICAL USE IN SPINAL CORD TORSION DYSTONIAS AND OTHER
BOTULINUM TOXIN**** NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √
INJURY INVOLUNTARY MOVEMENTS
BRINCIDOFOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PAEDIATRIC INDICATIONS (WHERE
BRODALIMUMAB NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE)
HEREDITARY ANGIOEDEMA - ACUTE NHS ENGLAND CLINICAL
C1 ESTERASE INHIBITORS NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
TREATMENT COMMISSIONING POLICY: B09/P/b
HEREDITARY ANGIOEDEMA - NHS ENGLAND CLINICAL
C1 ESTERASE INHIBITORS NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
PROPHYLACTIC TREATMENT COMMISSIONING POLICY: 16045/P
HEREDITARY ANGIOEDEMA -
AS PER NHS ENGLAND CLINICAL
C1 ESTERASE INHIBITORS PROPHYLACTIC TREATMENT IN NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
COMMISSIONING POLICY: 16045/P
CHILDREN (CINRYZE ONLY)
CRYOPYRIN ASSOCIATED PERIODIC CRYOPYRIN ASSOCIATED PERIODIC HIGHLY SPECIALISED HIGHLY SPECIALISED
CANAKINUMAB NHS ENGLAND IMMUNOMODULATING DRUGS HIGHLY SPECIALISED DATABASE √
SYNDROME SYNDROME SERVICE SPECIFICATION CRITERIA ONLY CRITERIA ONLY

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 2 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
NOT ROUTINELY COMMISSIONED
CANAKINUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND IMMUNOMODULATING DRUGS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(TA302)
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
CARGLUMIC ACID UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
CARNITINE CARNITINE DEFICIENCY NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
NUMBER OF PATIENTS TREATED
CASPOFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY

CONGENITAL FACTOR XIII A-SUBUNIT


CATRIDECACOG NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DEFICIENCY

CERALIFIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LYSOSOMAL STORAGE DISORDER
CERLIPONASE ALFA NEURONAL CEROID LIPOFUSCINOSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS
CERTOLIZUMAB PEGOL PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CETUXIMAB CANCER NHS ENGLAND ANTINEOPLASTIC DRUGS TA145, TA176, TA439, TA473 NICE NICE SACT √ √
CEREBROTENDINOUS DRUGS USED IN METABOLIC
CHENODEOXYCHOLIC ACID NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
XANTHOMATOSIS (CTX) DISORDERS
DRUGS USED IN METABOLIC
CHENODEOXYCHOLIC ACID PRIMARY BILIARY CIRRHOSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
INBORN ERRORS IN PRIMARY BILE DRUGS USED IN METABOLIC
CHOLIC ACID NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ACID SYNTHESIS DISORDERS
NUMBER OF PATIENTS TREATED
CIDOFOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
CIPROFLOXACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CIPROFLOXACIN LIPOSOMAL CYSTIC FIBROSIS
NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(INHALED)
CLADRIBINE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA492 NICE NICE NICE AUDIT √ √****
PULMONARY LANGERHANS
CLADRIBINE NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HISTIOCYTOSIS
NHS ENGLAND CLINICAL
HIV IN COMBINATION WITH OTHER ANTI-
COBICISTAT NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
F03/P/b/AGREED REGIONAL GUIDELINES
PAEDIATRIC INDICATIONS (WHERE DRUGS AFFECTING THE IMMUNE
COBITOLIMOD NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE) RESPONSE
NHS ENGLAND CLINICAL
CO-CARELDOPA INTESTINAL GEL PARKINSON'S DISEASE NHS ENGLAND NEURODEGENERATIVE CONDITIONS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: D04/P/e
NHS ENGLAND CLINICAL
NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
COLISTIMETHATE SODIUM CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS COMMISSIONING POLICY: A01/P/b √* √*
NICE NICE NICE AUDIT
TA276
HEREDITARY ANGIOEDEMA - ACUTE NHS ENGLAND CLINICAL
CONESTAT ALFA NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
TREATMENT ONLY COMMISSIONING POLICY: B09/P/b
CRIZOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE TA 406, 422 NICE NICE SACT √
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
CYSTEAMINE (MERCAPTAMINE) NEPHROPATHIC CYSTINOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
DABRAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA321, 396 NICE NICE SACT √ (TA396) √
VIRAL HEPATITIS (B&C) &
DACLATASIVIR HEPATITIS C NHS ENGLAND TA 364 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
RESPIRATORY SYNCYTIAL VIRUS
DACLIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA441 NICE NICE NICE AUDIT √ √
HIV IN COMBINATION WITH OTHER ANTI-
DARUNAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
DARUNAVIR + HIV IN COMBINATION WITH OTHER ANTI-
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
COBICISTAT (REZOLSTA®) RETROVIRAL DRUGS
VIRAL HEPATITIS (B&C) &
DASABUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
NHS ENGLAND/ NICE TA 425, 426 NICE NICE
DASATINIB CANCER PROTEIN KINASE INHIBITORS SACT √
CDF CDF POLICY CDF CDF
NOT ROUTINELY COMMISSIONED
DECITABINE CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
(TA270)
DRUGS USED IN HYPOPLASTIC,
IRON CHELATION IN THALASSAEMIA NHS ENGLAND CLINICAL QUALITY DASHBOARD/ NATIONAL
DEFERASIROX NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √
AND SICKLE CELL COMMISSIONING POLICY 16070/P HAEMOGLOBINOPATHY REGISTRY
IRON OVERLOAD
DRUGS USED IN HYPOPLASTIC,
IRON CHELATION IN THALASSAEMIA NHS ENGLAND CLINICAL QUALITY DASHBOARD/ NATIONAL
DEFERIPRONE** NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √
AND SICKLE CELL COMMISSIONING POLICY 16070/P HAEMOGLOBINOPATHY REGISTRY
IRON OVERLOAD
NHS ENGLAND CLINICAL
DEFIBROTIDE HEPATIC VENO-OCCLUSIVE DISEASE NHS ENGLAND BLOOD-RELATED PRODUCTS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: B04/P/c
NHS ENGLAND CLINICAL
DELAMANID EXTENSIVELY DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: F04/P/a
NHS ENGLAND CLINICAL
DELAMANID MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: F04/P/a
DRUGS USED IN HYPOPLASTIC,
IRON CHELATION IN THALASSAEMIA NHS ENGLAND CLINICAL QUALITY DASHBOARD/ NATIONAL
DESFERRIOXAMINE** NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √
AND SICKLE CELL COMMISSIONING POLICY 16070/P HAEMOGLOBINOPATHY REGISTRY
IRON OVERLOAD

DEXRAZOXANE ANTHRACYCLINE EXTRAVASATION NHS ENGLAND IMMUNOMODULATING DRUGS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

DEXRAZOXANE ANTHRACYCLINE CARDIOTOXICITY NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND CLINICAL
DIBOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEIN NHS ENGLAND POLICY NHS ENGLAND POLICY AUDIT, BSR REGISTRY √
COMMISSIONING POLICY 16063/P
HIV IN COMBINATION WITH OTHER ANTI-
DIDANOSINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
DIMETHYL FUMARATE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA320 NICE NICE NICE AUDIT √ √****

NHS ENGLAND CLINICAL


HIV IN COMBINATION WITH OTHER ANTI-
DOLUTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
B06/P/b/AGREED REGIONAL GUIDELINES

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 3 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
HIV iN COMBINATION WITH OTHER ANTI-
DORAVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
NOT ROUTINELY COMMISSIONED
DORNASE ALFA PRIMARY CILIARY DYSKINESIA NHS ENGLAND MUCOLYTICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND POLICY 16029/P
NHS ENGLAND CLINICAL
DORNASE ALFA CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √*
COMMISSIONING POLICY: A01/P/b
DRISAPERSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS AFFECTING THE IMMUNE
DUPILUMAB ASTHMA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
HEREDITARY ANGIOEDEMA - ACUTE
ECALLANTIDE NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TREATMENT ONLY
ORGAN REJECTION POST KIDNEY PAROXYSMAL NOCTURNAL NOT ROUTINELY COMMISSIONED
ECULIZUMAB NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRANSPLANT HAEMOGLOBINURIA NHS ENGLAND POLICY: A07/P/b
C3 GLOMERULOPATHY (POST PAROXYSMAL NOCTURNAL NHS ENGLAND CLINICAL
ECULIZUMAB NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
TRANSPLANT) HAEMOGLOBINURIA COMMISSIONING POLICY: 16054/P

NHS ENGLAND CLINICAL


PAROXYSMAL NOCTURNAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
ECULIZUMAB AHUS NHS ENGLAND COMMISSIONING POLICY: E03/PS(HSS)/A √
HAEMOGLOBINURIA NICE NICE NICE
NICE HST1

NHS NATIONAL SPECIALISED


PAROXYSMAL NOCTURNAL PAROXYSMAL NOCTURNAL
ECULIZUMAB NHS ENGLAND COMMISSIONING TEAM SERVICE NSCT SERVICE SPEC NSCT SERVICE SPEC NSCT SERVICE SPEC √
HAEMOGLOBINURIA HAEMOGLOBINURIA
SPECIFICATION
DRUGS AFFECTING THE IMMUNE
EDRATIDE SLE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
HIV IN COMBINATION WITH OTHER ANTI-
EFAVIRENZ NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS

EFRALOCTOCOG ALFA /
EFMOROCTOCOG ALFA / FACTOR HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652, see also SSC 1818 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √
VIII FC FUSION PROTEIN (Elocta®)

EFTRENONACOG ALFA (Alprolix®) HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √

VIRAL HEPATITIS (B&C) &


ELBASVIR HEPATITIS C NHS ENGLAND TA 413 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
RESPIRATORY SYNCYTIAL VIRUS
DRUGS USED IN METABOLIC
ELIGLUSTAT GAUCHER'S DISEASE NHS ENGLAND HST5 NICE NICE HIGHLY SPECIALISED DATABASE √
DISORDERS
LYSOSOMAL STORAGE DISORDER MANAGED ACCESS MANAGED ACCESS
ELOSULFASE ALFA MUCOPOLYSACCHARIDOSIS IV TYPE A NHS ENGLAND NICE HST2 MANAGED ACCESS AGREEMENT √ √
DRUGS AGREEMENT AGREEMENT
ELTROMBOPAG ITP IN CHILDREN NHS ENGLAND PLATELET DISORDER DRUGS AS PER ADULT TA 293 NICE NICE NICE AUDIT √ √
HIV IN COMBINATION WITH OTHER ANTI-
ELVITEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
HIV IN COMBINATION WITH OTHER ANTI-
ELVUCITABINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
NON-ALCOHOLIC STEATOHEPATITIS DRUGS USED IN METABOLIC
EMRICASAN NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(NASH) FIBROSIS DISORDERS
HIV IN COMBINATION WITH OTHER ANTI-
EMTRICITABINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
HIV IN COMBINATION WITH OTHER ANTI-
EMTRICITABINE +TENOFOVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
EMTRICITABINE + TENOFOVIR HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
ALAFENAMIDE DESCOVY® RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
EMTRICITABINE + RILPIVIRINE +
HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
TENOFOVIR ALAFENAMIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
(ODEFSEY®)
HIV IN COMBINATION WITH OTHER ANTI-
ENFUVIRTIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
VIRAL HEPATITIS (B&C) &
ENTECAVIR HEPATITIS B NHS ENGLAND TA153 & IN PROGRESS NICE NICE NICE AUDIT √
RESPIRATORY SYNCYTIAL VIRUS
TA316, TA 377 (SEE ALSO SSC1439)
NICE/NHS ENGLAND POLICY NICE
ENZALUTAMIDE CANCER NHS ENGLAND HORMONE ANTAGONISTS BOTH: ONLY IN ABIRATERONE NAÏVE SACT √
PATIENTS
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NHS ENGLAND CLINICAL
EPOPROSTENOL (5) NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION COMMISSIONING POLICY: A11/P/c
HYPERTENSION
EPRATUZUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EPRODISATE AMYLOIDOSIS NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EPTOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEIN NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA162, TA227, TA 374& IN PROGRESS
ERLOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE NICE SACT √
NHSE LETTER
NHS ENGLAND CLINICAL
ETANERCEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY: E03/P/d; TA NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
373
PAEDIATRIC INDICATIONS OR (WHERE AS PER TA455 OR ADULT TA'S (TA103,
ETANERCEPT NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √
ADULT TA AVAILABLE) TA130, TA143, TA199)
ETEPLIRSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

HIV IN COMBINATION WITH OTHER ANTI-


ETRAVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
PAEDIATRIC INDICATIONS (WHERE DRUGS AFFECTING THE IMMUNE
ETROLIZUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE) RESPONSE
EVEROLIMUS (AFINITOR®) CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA421, TA432, TA449, TA498 NICE NICE SACT √ √
PREVENTING ORGAN REJECTION IN NOT ROUTINELY COMMISSIONED
EVEROLIMUS (CERTICAN®) NHS ENGLAND PROTEIN KINASE INHIBITORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LIVER TRANSPLANTATION (TA348)
PREVENTING ORGAN REJECTION IN NOT ROUTINELY COMMISSIONED NHS
EVEROLIMUS (CERTICAN®) NHS ENGLAND PROTEIN KINASE INHIBITORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HEART TRANSPLANTATION ENGLAND POLICY 16016/P
SUBEPENDYMAL GIANT CELL
NHS ENGLAND CLINICAL
EVEROLIMUS (VOTUBIA®) ASTROCYTOMA (SEGA) ASSOCIATED NHS ENGLAND PROTEIN KINASE INHIBITORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: 16066/P
WITH TUBULAR SCLEROSIS
RENAL ANGIOMYOLIPOMA NHS ENGLAND CLINICAL
EVEROLIMUS (VOTUBIA®) ASSOCIATED WITH TUBULAR NHS ENGLAND PROTEIN KINASE INHIBITORS COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
SCLEROSIS B14X09L

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 4 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
AS NICE TA 394
HOMOZYGOUS FAMILIAL
EVOLOCUMAB NHS ENGLAND LIPID-REGULATING DRUGS (FOLLOW GUIDANCE FOR NICE NICE NICE AUDIT √
HYPERCHOLESTEROLAEMIA
HETEROZYGOUS FH)

TREATMENT OF ADULT PATIENTS WITH


EX-VIVO EXPANDED AUTOLOGOUS MODERATE TO SEVERE LIMBAL STEM
HUMAN CORNEAL EPITHELIAL CELL DEFICIENCY (LSCD), UNILATERAL NHS ENGLAND ATMP TA 467 NICE NICE NICE AUDIT √ √
CELLS CONTAINING STEM CELLS OR BILATERAL, DUE TO PHYSICAL OR
CHEMICAL OCULAR BURNS

AS PER BCSH GUIDELINES FOR


FACTOR IX NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
SPECIALISED INDICATIONS
AS PER BCSH GUIDELINES FOR
FACTOR VII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
SPECIALISED INDICATIONS
AS PER BCSH GUIDELINES FOR
FACTOR VIIA NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
SPECIALISED INDICATIONS
AS PER BCSH GUIDELINES FOR
FACTOR VIII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES, see also SSC 1818 BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
SPECIALISED INDICATIONS
FACTOR VIII INHIBITOR BYPASSING AS PER BCSH GUIDELINES FOR
NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR (FEIBA) SPECIALISED INDICATIONS
AS PER BCSH GUIDELINES FOR
FACTOR XIII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
SPECIALISED INDICATIONS
NOT ROUTINELY COMMISSIONED
FAMPRIDINE MULTIPLE SCLEROSIS NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √****
NHS ENGLAND POLICY: 16010/P
AS PER BCSH GUIDELINES FOR
FIBRINOGEN NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
SPECIALISED INDICATIONS
FIBROBLAST GROWTH FACTOR 1
SOMATOSTATIN ANALOGUE NHS ENGLAND SOMATOSTATIN ANALOGUES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GENE THERAPY
PAEDIATRIC INDICATIONS (WHERE DRUGS AFFECTING THE IMMUNE
FILGOTINIB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE) RESPONSE
HIGHLY SPECIALISED HIGHLY SPECIALISED
FILGRASTIM BARTH SYNDROME NHS ENGLAND DRUGS USED IN NEUTROPENIA HIGHLY SPECIALISED CRITERIA ONLY √
CRITERIA ONLY CRITERIA ONLY
NUMBER OF PATIENTS TREATED
PROPORTION GIVEN FOR SPC
FILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA SPC TRUST GUIDELINES TRUST GUIDELINES INDICATIONS WITHIN POLICY √
PRODUCT WITH LOWEST
ACQUISITION COST TO BE USED
VIRAL HEPATITIS (B&C) &
FILIBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
TA254
FINGOLIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
NHS ENGLAND POLICY: D04/P/b
ANAEMIAS AND SOME OTHER BLOOD
FITUSIRAN HAEMOPHILIA A AND B NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
FLEBOGAMMA AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
FLEBOGAMMADIF AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
FORIGERIMOD ACETATE SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HIV IN COMBINATION WITH OTHER ANTI-
FOSAMPRENAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NUMBER OF PATIENTS TREATED
FOSCARNET CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
HIV iN COMBINATION WITH OTHER ANTI-
FOSTEMSAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
GALSULFASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
GAMMAGARD AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
GAMMANORM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
GAMMAPLEX AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
GAMUNEX AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
NUMBER OF PATIENTS TREATED
GANCICLOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
DRUGS AFFECTING THE IMMUNE
GANETESPIB CANCER NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
RESPONSE
GEFITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA192 NICE NICE SACT √
GEVOKIZUMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GLATIRAMER MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA32 & NHS ENGLAND POLICY: D04/P/b NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER NHSE POLICY √ √****

VIRAL HEPATITIS (B&C) &


GLECAPREVIR HEPATITIS C NHS ENGLAND NICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
RESPIRATORY SYNCYTIAL VIRUS
METHOTREXATE INDUCED RENAL NHS ENGLAND CLINICAL
GLUCARPIDASE NHS ENGLAND POISONING NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
DYSFUNCTION COMMISSIONING POLICY: B15/P/a
DRUGS USED IN METABOLIC
GLYCEROL PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
GLYCOPEGYLATED FACTOR IX HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GOLIMUMAB PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS AS PER ADULTS TA'S (TA220, TA233) NICE NICE NICE AUDIT √
GRANULOCYTE-MACROPHAGE
ANTIBODY-POSITIVE PULMONARY
COLONY-STIMULATING FACTOR NHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ALVEOLAR PROTEINOSIS
(LEUKINE® - IMPORT)
GRAZOPREVIR VIRAL HEPATITIS (B&C) &
HEPATITIS C NHS ENGLAND TA 413 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
RESPIRATORY SYNCYTIAL VIRUS
HIV VACCINE HIV INFECTION PROPHYLAXIS NHS ENGLAND VACCINES AND ANTISERA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 5 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
HIZENTRA AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
HUMAN (HAEM) ARGINATE HEPATIC PORPHYRIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
HUMAN HETEROLOGOUS LIVER DRUGS USED IN METABOLIC
UREA CYCLE DISORDERS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CELLS DISORDERS
HUMAN PARATHYROID HORMONE- MALE AND JUVENILE OSTEOPOROSIS DRUGS AFFECTING BONE
NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RELATED PROTEIN ANALOGUE HYPOPARATHYROIDISM METABOLISM

INTRAVENOUS/SUBCUTANEOUS
HYQVIA AS PER NATIONAL DMP NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HUMAN NORMAL IMMUNOGLOBULINS
HIV iN COMBINATION WITH OTHER ANTI-
IBALIZUMAB NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
HEREDITARY ANGIOEDEMA - ACUTE NHS ENGLAND CLINICAL
ICATIBANT NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
TREATMENT ONLY COMMISSIONING POLICY: B09/P/b
HEREDUTARY ANGIOEDEMA - NHS ENGLAND CLINICAL
ICATIBANT NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
PROPHYLACTIC TREATMENT COMMISSIONING POLICY: 16045/P
IDEBENONE DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED


IDURSULFASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NHS ENGLAND CLINICAL
ILOPROST (5) NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION COMMISSIONING POLICY: A11/P/c
HYPERTENSION
IMATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA70, TA86, TA251, TA326 NICE NICE SACT √

CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL


IMATINIB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
DISEASE COMMISSIONING POLICY:16069/P
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
IMIGLUCERASE GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
HIV IN COMBINATION WITH OTHER ANTI-
INDINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NHS ENGLAND CLINICAL
INFLIXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: E03/P/d
NOT ROUTINELY COMMISSIONED
(NHS ENGLAND CLINICAL
INFLIXIMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
COMMISSIONING POLICY: D12/P/a &
D12/P/a)
AS PER ADULT TA'S (TA130, TA134,
PAEDIATRIC INDICATIONS (WHERE
INFLIXIMAB NHS ENGLAND CYTOKINE MODULATORS TA140, TA143, TA163, TA187, TA199, NICE NICE NICE AUDIT √ √
ADULT TA AVAILABLE)
TA329)
CONNECTIVE TISSUE DISEASE - NOT ROUTINELY COMMISSIONED -
INFLIXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INTERSTITAL LUNG DISEASE POLICY IN PROGRESS
INFLIXIMAB CROHN'S DISEASE IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS TA187 NICE NICE NICE AUDIT √
INFLIXIMAB GRAFT VERSUS HOST DISEASE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB RENAL NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB SARCOIDOSIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NOT ROUTINELY COMMISSIONED - NHS
INFLIXIMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENGLAND POLICY 16018/P
HIGHLY SPECIALISED HIGHLY SPECIALISED
INFLIXIMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √
CRITERIA ONLY CRITERIA ONLY
INTERFERON ALFA HEPATITIS B AND C NHS ENGLAND IMMUNOMODULATING DRUGS TA75 NICE NICE NICE AUDIT √
TA32
INTERFERON BETA MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER NHSE POLICY √ √****
NHS ENGLAND POLICY: D04/P/b
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
INTRATECT AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
NUMBER OF PATIENTS TREATED
FUNGAL INFECTION (LICENSED
ISAVUCONAZOLE NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS)
INDICATIONS WITHIN POLICY
NHS ENGLAND CLINICAL
IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS COMMISSIONING POLICY: A01/P/c, NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
16049/P
IXAZOMIB AMYLOIDOSIS NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IXAZOMIB MULTIPLE MYELOMA CDF CANCER EXCLUSION CDF (TA 505) CDF CDF SACT √ √
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
KIOVIG AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
VIRAL HEPATITIS (B&C) &
LAMIVUDINE HEPATITIS B NHS ENGLAND CG165 NICE NICE NICE AUDIT √
RESPIRATORY SYNCYTIAL VIRUS
HIV IN COMBINATION WITH OTHER ANTI-
LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
PRODUCT WITH LOWEST
LANREOTIDE CANCER NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
PROCUREMENT COST TO BE USED
HIGHLY SPECIALISED HIGHLY SPECIALISED
LANREOTIDE CONGENITAL HYPERINSULINISM NHS ENGLAND SOMATOSTATIN ANALOGUES HIGHLY SPECIALISED CRITERIA ONLY √
CRITERIA ONLY CRITERIA ONLY
PRODUCT WITH LOWEST
LANREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ √
PROCUREMENT COST TO BE USED
LAPATINIB CANCER CDF PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED CDIFR CDIFR SACT √
LAQUINIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √****
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
LARONIDASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
LEBRIKIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND/ TA171, TA322 NICE NICE
LENALIDOMIDE CANCER IMMUNOMODULATING DRUGS SACT √
CDF CDF POLICY CDF CDF
HIGHLY SPECIALISED HIGHLY SPECIALISED
LENALIDOMIDE POEMS NHS ENGLAND IMMUNOMODULATING DRUGS HIGHLY SPECIALISED CRITERIA ONLY √
CRITERIA ONLY CRITERIA ONLY

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 6 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
NUMBER OF PATIENTS TREATED
PROPORTION GIVEN FOR SPC
LENOGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA SPC TRUST GUIDELINES TRUST GUIDELINES INDICATIONS WITHIN POLICY √
PRODUCT WITH LOWEST
ACQUISITION COST TO BE USED
HIGHLY SPECIALISED HIGHLY SPECIALISED
LENOGRASTIM BARTH SYNDROME NHS ENGLAND DRUGS USED IN NEUTROPENIA HIGHLY SPECIALISED CRITERIA ONLY √
CRITERIA ONLY CRITERIA ONLY
LETERMOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LEVOFLOXACIN (INHALED) CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NOT ROUTINELY COMMISSIONED -
LIPEGFILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
POLICY IN PROGRESS
HYPONATRAEMIA AND OTHER POSTERIOR PITUITARY HORMONES
LIXIVAPTAN NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENDOCRINE USES AND ANTAGONISTS
HOMOZYGOUS FAMILIAL
LOMITAPIDE NHS ENGLAND LIPID-REGULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERCHOLESTEROLEMIA
LONAFARNIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HIV IN COMBINATION WITH OTHER ANTI-
LOPINAVIR + RITONAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NOT ROUTINELY COMMISSIONED
LUMACAFTOR AND IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA IN PROGRESS
GROWTH HORMONE & GROWTH
MACIMORELIN GROWTH FAILURE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HORMONE RECEPTOR ANTAGONIST
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NHS ENGLAND CLINICAL
MACITENTAN NHS ENGLAND DRUGS/PULMANORY ARTERIAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERTENSION COMMISSIONING POLICY: A11/P/c
HYPERTENSION
NHS ENGLAND CLINICAL
NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
MANNITOL CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS COMMISSIONING POLICY: A01/P/b √
NICE NICE NICE AUDIT
TA266
HIV IN COMBINATION WITH OTHER ANTI-
MARAVIROC NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
MASITINIB PANCREATIC CANCER/GIST NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PAEDIATRIC INDICATIONS (WHERE DRUGS AFFECTING THE IMMUNE
MAVRILIMUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE) RESPONSE
GROWTH HORMONE & GROWTH NHS ENGLAND CLINICAL
MECASERMIN GROWTH FAILURE NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HORMONE RECEPTOR ANTAGONIST COMMISSIONING POLICY: EO3/P/a
TA431
MEPOLIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NICE NICE NICE AUDIT √ √
METRELEPTIN DYSLIPIDAEMIA NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NUMBER OF PATIENTS TREATED
MICAFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
DRUGS USED IN METABOLIC
MIGALASTAT FABRY'S DISEASE NHS ENGLAND NICE HST4 NICE NICE HIGHLY SPECIALISED DATABASE √
DISORDERS
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
MIGLUSTAT GAUCHER'S DISEASE/ NIEMANN-PICK NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
MOMELOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VIRAL HEPATITIS (B&C) &
MOTAVIZUMAB RSV PROPHYLAXIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
TA127
NATALIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
NHS ENGLAND POLICY: D04/P/b
HIV IN COMBINATION WITH OTHER ANTI-
NELFINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
HIV IN COMBINATION WITH OTHER ANTI-
NEVIRAPINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NILOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA241, TA251 NICE NICE SACT √
NINTEDANIB OVARIAN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED CDIFR CDIFR SACT √
NINTEDANIB (OFEV®) IDIOPATHIC PULMONARY FIBROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA 379 NICE NICE NICE AUDIT √ √
NINTEDANIB (VARGATEF®) NON-SMALL-CELL LUNG CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA347 NICE NICE SACT √
VIRAL HEPATITIS (B&C) &
NITAZOXANIDE HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
NITISINONE ALKAPTONURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
NITISINONE TYROSINAEMIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL
NITRIC OXIDE NHS ENGLAND DRUGS/PULMANORY ARTERIAL AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
HYPERTENSION
HYPERTENSION
NONACOG ALPHA (BeneFIX) HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
NONACOG BETA PEGOL HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
NORMAL IMMUNOGLOBULIN AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
DRUGS USED IN METABOLIC
OBETICHOLIC ACID PRIMARY BILIARY CIRRHOSIS NHS ENGLAND TA443 NICE NICE NICE AUDIT √ √
DISORDERS
DRUGS AFFECTING THE IMMUNE
OCRELIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
OCTAGAM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
OCTOCOG ALFA HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES: See also SSC 1818 AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

GROWTH HORMONE & GROWTH


OCTREOLIN ACROMEGALY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HORMONE RECEPTOR ANTAGONIST

PRODUCT WITH LOWEST


OCTREOTIDE CANCER NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
PROCUREMENT COST TO BE USED
HIGHLY SPECIALISED HIGHLY SPECIALISED
OCTREOTIDE CONGENITAL HYPERINSULINISM NHS ENGLAND SOMATOSTATIN ANALOGUES HIGHLY SPECIALISED CRITERIA ONLY √
CRITERIA ONLY CRITERIA ONLY
PRODUCT WITH LOWEST
OCTREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
PROCUREMENT COST TO BE USED

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 7 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
OFATUMUMAB CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA344 NICE NICE SACT √
OFATUMUMAB PEMPHIGUS VULGARIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OLESOXIME SPINAL MUSCULAR ATROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OMALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY TA278 NICE NICE NICE AUDIT √ √
OMBITASVIR/PARITAPREVIR/RITON VIRAL HEPATITIS (B&C) &
HEPATITIS C NHS ENGLAND TA 365 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
AVIR + DASABUVIR + RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS
OSILODROSTAT CUSHING'S DISEASE NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OZANIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PACRITINIB MYELOFIBROSIS NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VIRAL HEPATITIS (B&C) & JCVI GUIDELINES
PALIVIZUMAB RSV PROPHYLAXIS NHS ENGLAND AS PER SPECIFICATION AS PER SPECIFICATION √ √
RESPIRATORY SYNCYTIAL VIRUS PHE SPECIFICATION
PARA-AMINOSALICYLIC ACID NHS ENGLAND CLINICAL
MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: F04/P/a
SPECIALIST ENDOCRINOLOGY
PARATHYROID HORMONE NHS ENGLAND PARATHYROID HORMONE AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
CONDITIONS
PARENTERAL NUTRITION (HOME
INTESTINAL FAILURE NHS ENGLAND PARENTERAL NUTRITION AS PER BLUETEQ FORM AS PER BLUETEQ FORM AS PER BLUETEQ FORM AUDIT √ √
USE)

ONLY WHEN DURATION OF PN IS > 14


DAYS OR INITIATED PRIOR TO
PARENTERAL NUTRITION INTESTINAL FAILURE; INADEQUATE/
NHS ENGLAND PARENTERAL NUTRITION ADMISSION. ADULTS; SEE ALSO CG32. TRUST GUIDELINES TRUST GUIDELINES √
(INPATIENT USE) UNSAFE ENTERAL FEEDING
SEE ALSO 'MANUAL FOR PRESCRIBED
SPECIALISED SERVICES'

VIRAL HEPATITIS (B&C) &


PARITAPREVIR HEPATITIS C NHS ENGLAND NICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
RESPIRATORY SYNCYTIAL VIRUS
NOT ROUTINELY COMMISSIONED
PASIREOTIDE ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND POLICY 16003/P
NHS ENGLAND CLINICAL
PASIREOTIDE CUSHING'S DISEASE NHS ENGLAND SOMATOSTATIN ANALOGUES NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY: 16052/P
PAZOPANIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA215 NICE NICE SACT √
NHS ENGLAND CLINICAL
VIRAL HEPATITIS (B&C) & COMMISSIONING POLICY: B07/P/a; TA75,
PEG INTERFERON ALFA HEPATITIS B AND C NHS ENGLAND NICE NICE NICE AUDIT √
RESPIRATORY SYNCYTIAL VIRUS TA96, TA106, TA200, TA 300
CG165
PEGFILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

ROUTINELY COMMISSIONED AS PER


PEGINTERFERON BETA-1A MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS SSC1534: MULTIPLE SCLEROSIS FIRST NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
LINE DISEASE MODIFYING AGENTS
PEGINTERFERON LAMBDA-1A HEPATITIS C NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPOTHALMIC & ANTERIOR
NHS ENGLAND CLINICAL
PEGVISOMANT ACROMEGALY NHS ENGLAND PITUITARY HORMONES & ANTI- NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY: 16050/P
OESTROGENS
TA 357, TA366, TA428 NICE NICE
PEMBROLIZUMAB CANCER INDICATIONS NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF POLICY (TA 447) CDF CDF
PIRFENIDONE IDIOPATHIC PULMONARY FIBROSIS NHS ENGLAND PULMONARY FIBROSIS TA 504 (SPECIALIST CENTRE ONLY) NICE NICE NICE AUDIT √ √
NUMBER OF PATIENTS TREATED
NHS ENGLAND CLINICAL
DRUGS AFFECTING THE IMMUNE NUMBER OF PATIENTS
PLERIXAFOR STEM CELL MOBILISATION NHS ENGLAND COMMISSIONING POLICY: B04/P/b, NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
RESPONSE SUCCESSFULLY TRANSPLANTED
16064/P
STAGE DRUG UTILISED
POMALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA427 NICE NICE SACT √ √
POMALIDOMIDE MYELOFIBROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PONATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA451 NICE NICE SACT √ √
DRUGS USED FOR NEUROMUSCULAR
PONESIMOD MULTIPLE SCLEROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
PRODUCT WITH LOWEST
PORACTANT ALFA RESPIRATORY DISTRESS SYNDROME NHS ENGLAND PULMONARY SURFACTANTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
PROCUREMENT COST TO BE USED

NUMBER OF PATIENTS TREATED


POSACONAZOLE FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
PRETOMANID MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
PRIVIGEN AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
AS PER BCSH GUIDELINES FOR
PROTEIN C NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
SPECIALISED INDICATIONS
AS PER BCSH GUIDELINES FOR
PROTHROMBIN COMPLEX NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
SPECIALISED INDICATIONS
HIV IN COMBINATION WITH OTHER ANTI-
RALTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
GOUT AND CYTOTOXIC-INDUCED
RASBURICASE HYPERURICAEMIA NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
HYPERURICAEMIA
REGORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA488 NICE NICE SACT √ √
RESLIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY TA479 NICE NICE NICE AUDIT √ √
LYSOSOMAL STORAGE DISORDER
REVEGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS
NHS ENGLAND CLINICAL NICE AUDIT
VIRAL HEPATITIS (B&C) &
RIBAVIRIN HEPATITIS C NHS ENGLAND COMMISSIONING POLICY: B07/P/a; TA75, NICE NICE PRODUCT WITH LOWEST √
RESPIRATORY SYNCYTIAL VIRUS
TA106, TA200 PROCUREMENT COST TO BE USED
RIGOSERTIB MDS/PANCREATIC CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CRYOPYRIN-ASSOCIATED PERIODIC
RILONACEPT NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SYNDROMES
HIV IN COMBINATION WITH OTHER ANTI-
RILPIVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NHS ENGLAND CLINICAL
RIOCIGUAT NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
HYPERTENSION (CTEPH) COMMISSIONING POLICY: A11/P/c
HYPERTENSION
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NHS ENGLAND CLINICAL
RIOCIGUAT NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
HYPERTENSION COMMISSIONING POLICY: 16055/P
HYPERTENSION
HIV IN COMBINATION WITH OTHER ANTI-
RITONAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 8 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
STEROID SENSITIVE NEPHROTIC NHS ENGLAND CLINICAL
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
SYNDROME COMMISSIONING POLICY: E03/P/b
STEROID RESISTANT NEPHROTIC NHS ENGLAND CLINICAL
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
SYNDROME COMMISSIONING POLICY: E03/P/c
NOT ROUTINELY COMMISSIONED -
RITUXIMAB PRIMARY SJOGREN'S SYNDROME (PSS) NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
POLICY IN PROGRESS
CHRONIC INFLAMMATORY NOT ROUTINELY COMMISSIONED -
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DEMYELINATING POLYNEUROPATHY POLICY IN PROGRESS
NHS ENGLAND CLINICAL
RITUXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: E03/P/d
NHS ENGLAND CLINICAL
RITUXIMAB ACQUIRED HAEMOPHILIA NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY: F02/P/a
TA308 NICE/ NHS ENGLAND NICE/ NHS ENGLAND
RITUXIMAB ANCA-POSITIVE VASCULITIS NHS ENGLAND CYTOKINE MODULATORS NICE/ NHS ENGLAND POLICY √
NHS ENGLAND POLICY: A13/P/a POLICY POLICY
CONNECTIVE TISSUE DISEASE - NOT ROUTINELY COMMISSIONED -
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INTERSTITIAL LUNG DISEASE POLICY IN PROGRESS
CYTOPENIA COMPLICATING PRIMARY NHS ENGLAND CLINICAL
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
IMMUNODEFICIENCY COMMISSIONING POLICY:16044/P
CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
DISEASE COMMISSIONING POLICY:16069/P
NHS ENGLAND CLINICAL
RITUXIMAB SLE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY: A13/PS/a
NHS ENGLAND CLINICAL
RITUXIMAB MYOSITIS NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY:16035/P
RITUXIMAB NEPHRITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RITUXIMAB NEUROMYELITIS OPTICA NHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √
ABO-INCOMPATIBLE KIDNEY
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √
TRANSPLANTS
PEMPHIGUS VULGARIS AND NHS ENGLAND CLINICAL
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
PEMPHIGOID DISEASE COMMISSIONING POLICY:16035/P
NHS ENGLAND CLINICAL
RITUXIMAB IMMUNOGLOBIN G4 RELATED DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY:16057/P
TA65, TA137, TA174, TA193,
TA65, TA137, TA174, TA193,
TA65, TA137, TA174, TA193, TA226, TA243 TA226, TA243
RITUXIMAB IV CANCER NHS ENGLAND CYTOKINE MODULATORS TA226, TA243 SACT √
NHS ENGLAND CDF LETTER NHS ENGLAND CDF
NHS ENGLAND CDF LETTER
LETTER

AS PER CIRCULAR IE ONLY


RITUXIMAB SUBCUTANEOUS
CANCER NHS ENGLAND CYTOKINE MODULATORS COMMISSIONED FOR FOLLICULAR AS PER CIRCULAR AS PER CIRCULAR SACT √
FORMULATION
LYMPHOMA MAINTENANCE TREATMENT
ROMIPLOSTIM ITP IN CHILDREN NHS ENGLAND PLATELET DISORDER DRUGS AS PER ADULT TA 221 NICE NICE NICE AUDIT √ √
VIRAL HEPATITIS (B&C) &
ROPEGINTERFERON ALFA-2b HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
DRUGS USED IN HYPOPLASTIC,
ROXADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HAEMOLYTIC, AND RENAL ANAEMIAS
RUXOLITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 386 NICE NICE SACT √
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
SANDOGLOBULIN AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
NOT ROUTINELY COMMISSIONED
DRUGS USED IN METABOLIC
SAPROPTERIN CHILDREN WITH PHENYLKETONURIA NHS ENGLAND (NHS ENGLAND CLINICAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
COMMISSIONING POLICY: E06/P/a)
DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL
SAPROPTERIN MATERNAL PHENYLKETONURIA NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY HIGHLY SPECIALISED DATABASE √
DISORDERS COMMISSIONING POLICY: E12/P/a
HIV IN COMBINATION WITH OTHER ANTI-
SAQUINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
PAEDIATRIC INDICATIONS (WHERE
SARILUMAB NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE)
DRUGS USED IN METABOLIC NOT ROUTINELY COMMISSIONED
SEBELIPASE ALFA LYSOSOMAL ACID LIPASE DEFICIENCY NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS NICE HST IN PROGRESS
SECUKINUMAB PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NOT ROUTINELY COMMISSIONED
SELEXIPAG NHS ENGLAND DRUGS/PULMANORY ARTERIAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERTENSION NHS ENGLAND POLICY 160017/P
HYPERTENSION
VIRAL HEPATITIS (B&C) &
SETROBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
DRUGS USED IN METABOLIC
SIALIC ACID MYOPATHY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS

VASODILATOR ANTIHYPERTENSIVE AS PER POLICY


PULMONARY ARTERIAL NHS ENGLAND CLINICAL
SILDENAFIL NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY PRODUCT WITH LOWEST √
HYPERTENSION COMMISSIONING POLICY: A11/P/c
HYPERTENSION PROCUREMENT COST TO BE USED
SIMEPREVIR/PEGINTERFERON + VIRAL HEPATITIS (B&C) &
HEPATITIS C NHS ENGLAND TA 331 NICE NICE HEPATITIS C MDS √ √
RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS

PAEDIATRIC INDICATIONS (WHERE DRUGS AFFECTING THE IMMUNE


SIRUKUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE) RESPONSE

NARCOLEPSY - PEADIATRIC SERVICES NHS ENGLAND CLINICAL


SODIUM OXYBATE NHS ENGLAND HYPNOTICS & ANXIOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
ONLY COMMISSIONING POLICY: 16065/P
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
SODIUM PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
SOFOSBUVIR/DACLATASVIR + VIRAL HEPATITIS (B&C) &
HEPATITIS C NHS ENGLAND TA 364 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS
SOFOSBUVIR/LEDIPASVIR +/- VIRAL HEPATITIS (B&C) &
HEPATITIS C NHS ENGLAND TA 363 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS
SOFOSBUVIR/PEGINTERFERON+ VIRAL HEPATITIS (B&C) &
HEPATITIS C NHS ENGLAND TA 330 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS
VIRAL HEPATITIS (B&C) &
SOFOSBUVIR/VELPATASVIR HEPATITIS C NHS ENGLAND TA 430 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
RESPIRATORY SYNCYTIAL VIRUS
SORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 474 NICE NICE SACT √ √

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 9 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
HIV IN COMBINATION WITH OTHER ANTI-
STAVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
SUBCUVIA AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)

CLINICAL GUIDELINES FOR


INTRAVENOUS/SUBCUTANEOUS
SUBGAM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)

SUNITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA169, TA179, TA449 NICE NICE SACT √ √
SUSOCTOCOG ALFA (OBIZUR) HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TABALUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NHS ENGLAND CLINICAL
TADALAFIL NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION COMMISSIONING POLICY: A11/P/c
HYPERTENSION
TAFAMANDIS AMYLOIDOSIS NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED


TALIGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
VIRAL HEPATITIS (B&C) &
TARIBAVIRIN HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
TEDUGLUTIDE SHORT BOWEL SYNDROME NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VIRAL HEPATITIS (B&C) &
TELAPREVIR HEPATITIS C NHS ENGLAND TA252 NICE NICE HEPATITIS C MDS √ √
RESPIRATORY SYNCYTIAL VIRUS
VIRAL HEPATITIS (B&C) & NOT ROUTINELY COMMISSIONED
TELBIVUDINE HEPATITIS B NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS (TA154)
TEMSIROLIMUS CANCER CDF PROTEIN KINASE INHIBITORS CDF POLICY CDF CDF SACT √
HIV IN COMBINATION WITH OTHER ANTI-
RETROVIRAL DRUGS TA173 (FOR HEPATITIS B)/AGREED BHIVA GUIDELINES (8) BHIVA GUIDELINES (8)
TENOFOVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS HARS DATASET √
HEPATITIS B +/- OTHER ANTI- REGIONAL GUIDELINES FOR HIV NICE NICE
RETROVIRAL DRUGS
TENOFOVIR ALAFENAMIDE HEPATITIS B NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
TENOFOVIR ALAFENAMIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
TENOFOVIR ALAFENAMIDE +
HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
COBICISTAT + ELVITEGRAVIR + NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
EMTRICITABINE (GENVOYA®)
TENOFOVIR DISOPROXIL + NHS ENGLAND CLINICAL
HIV IN COMBINATION WITH OTHER ANTI-
COBICISTAT + ELVITEGRAVIR + NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
EMTRICITABINE (STRIBILD®) F03/P/b/AGREED REGIONAL GUIDELINES
TENOFOVIR + EMTRICITABINE + HIV IN COMBINATION WITH OTHER ANTI-
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
EFAVIRENZ RETROVIRAL DRUGS
TENOFOVIR + EMTRICITABINE + HIV IN COMBINATION WITH OTHER ANTI-
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RILPIVIRINE RETROVIRAL DRUGS
TA303
TERIFLUNOMIDE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NICE NICE NICE AUDIT √ √****
NHS ENGLAND POLICY: D04/P/b
DRUGS AFFECTING BONE NOT ROUTINELY COMMISSIONED
TERIPARATIDE OSTEOGENESIS IMPERFECTA NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM NHS ENGLAND POLICY: 16002/P
DRUGS AFFECTING BONE
TERIPARATIDE MALE AND JUVENILE OSTEOPOROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
TETRAHYDROBIOPTERIN PHENYLKETONURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
TEZACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
THALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA228 NICE NICE SACT √

THROMBIN PSEUDOANEURYSM NHS ENGLAND BLOOD-RELATED PRODUCTS IPG060 IPG060 NICE √

HIV IN COMBINATION WITH OTHER ANTI-


TIPRANAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NHS ENGLAND CLINICAL
NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
TOBRAMYCIN CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS COMMISSIONING POLICY: A01/P/b √* √*
NICE NICE NICE AUDIT
TA276
NHS ENGLAND CLINICAL
TOCILIZUMAB IV JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY: E03/P/d; TA NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
373
NHS ENGLAND CLINICAL
TOCILIZUMAB TAKAYASU ARTERITIS NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY 16056/P
NOT ROUTINELY COMMISSIONED NHS
TOCILIZUMAB GIANT CELL ARTERITIS NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENGLAND POLICY 16019/P
PAEDIATRIC INDICATIONS (WHERE
TOCILIZUMAB IV NHS ENGLAND CYTOKINE MODULATORS AS PER ADULT TA'S (TA247 and TA375) NICE NICE NICE AUDIT √
ADULT TA AVAILABLE)
PAEDIATRIC INDICATIONS (WHERE
TOFACITINIB NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE)
POSTERIOR PITUITARY HORMONES NHS ENGLAND CLINICAL
TOLVAPTAN HYPONATRAEMIA IN CANCER NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
AND ANTAGONISTS COMMISSIONING POLICY 16051/P
TRALOKINUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRENONACOG ALPHA HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL
TREPROSTINIL DIETHANOLAMINE NHS ENGLAND DRUGS/PULMANORY ARTERIAL NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERTENSION
HYPERTENSION
NOT ROUTINELY COMMISSIONED FOR
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NEW PATIENTS - NHS ENGLAND
TREPROSTINIL SODIUM NHS ENGLAND DRUGS/PULMANORY ARTERIAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERTENSION CLINICAL COMMISSIONING POLICY:
HYPERTENSION
A11/P/c
DRUGS USED IN METABOLIC
TRIENTENE WILSONS DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
AS PER BCSH GUIDELINES FOR
TUROCTOCOG ALFA (NovoEight) NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES: See also SSC 1818 BCSH GUIDELINES BCSH GUIDELINES √
SPECIALISED INDICATIONS
PAEDIATRIC INDICATIONS (OR WHERE DRUGS AFFECTING IMMUNE AS PER TA455 AND ADULT TA's (TA180,
USTEKINUMAB NHS ENGLAND NICE NICE NICE √ √
ADULT TA AVAILABLE) RESPONSE TA340)

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 10 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL

DRUGS USED IN HYPOPLASTIC,


VADADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HAEMOLYTIC, AND RENAL ANAEMIAS

NUMBER OF PATIENTS TREATED


VALGANCICLOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
SACT
VANDETANIB THYROID CANCER CDF PROTEIN KINASE INHIBITORS CDF POLICY CDF CDF √
CDF NATIONAL AUDIT
PAEDIATRIC INDICATIONS (WHERE
VEDOLIZUMAB NHS ENGLAND CYTOKINE MODULATORS AS PER ADULT TA's (TA 342, TA 352) NICE NICE NICE AUDIT √ √
ADULT TA AVAILABLE)

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED


VELAGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY

DRUGS AFFECTING BONE


VELCALCETIDE HYPERPARATHYROIDISM NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM
VEMURAFENIB MELANOMA NHS ENGLAND PROTEIN KINASE INHIBITORS TA269 NICE NICE NICE AUDIT √
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
VIGAM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
VIVAGLOBIN AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
VON WILLEBRAND FACTOR,
VON WILLEBRAND DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RECOMBINANT
NUMBER OF PATIENTS TREATED
VORICONAZOLE FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
CHRONIC PULMONARY HIGHLY SPECIALISED HIGHLY SPECIALISED
VORICONAZOLE NHS ENGLAND ANTIFUNGALS HIGHLY SPECIALISED CRITERIA ONLY √
ASPERGILLOSIS CRITERIA ONLY CRITERIA ONLY
NOT ROUTINELY COMMISSIONED - NHS
ZICONOTIDE INTRATHECAL ANALGESIA NHS ENGLAND NON-OPIOID ANALGESICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENGLAND POLICY 16011/P
HIV IN COMBINATION WITH OTHER ANTI-
ZIDOVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
HIV IN COMBINATION WITH OTHER ANTI-
ZIDOVUDINE + LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ZIDOVUDINE + LAMIVUDINE + HIV IN COMBINATION WITH OTHER ANTI-
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
ABACAVIR RETROVIRAL DRUGS
OTHER DRUGS NOT LISTED
UNDER PBR EXCLUSIONS
LAMBERT EATON MYASTHENIC
3,4 DIAMINOPYRIDINE NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
SYNDROME
AFLIBERCEPT CANCER NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER CDIFR APPROVAL AS PER CDIFR APPROVAL SACT √
TREATMENT OF BREAST CANCER
ALBUMIN BOUND PACLITAXEL PATIENTS WITH DOCUMENTED NHS ENGLAND CANCER EXCLUSION TA 476 NICE NICE SACT √ √
TAXANE HYPERSENSITIVITY
ATEZOLIZUMAB CANCER CDF CANCER EXCLUSION CDF (TA 492) CDF CDF SACT √ √
AUTOLOGOUS CHONDROCYTE
ARTICULAR CARTILAGE DEFECT NHS ENGLAND TA 477 NICE NICE NICE AUDIT √
IMPLANTATION
TRANSPLANT IMMUNOSUPPRESSION NEW PATIENTS ONLY UNTIL FORMAL
AZATHIOPRINE NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √* √*
ONLY REPATRIATION AGREED
NHS ENGLAND/ TA216 NICE NICE
BENDAMUSTINE CANCER CANCER EXCLUSION SACT √
CDF CDF POLICY CDF CDF
BLINATUMOMAB CANCER NHS ENGLAND CANCER EXCLUSION TA450 NICE NICE SACT √ √
NHS ENGLAND/ TA446, TA478 NICE NICE
BRENTUXIMAB CANCER CANCER EXCLUSION SACT √ √
CDF CDF POLICY CDF CDF
CABAZITAXEL CANCER NHS ENGLAND CANCER EXCLUSION TA 391 NICE NICE SACT √ √
TA 463 NICE NICE
CABOZANTINIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF POLICY CDF CDF
CARFILZOMIB CANCER NHS ENGLAND CANCER EXCLUSION TA 457 NICE NICE SACT √ √
CERITINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 395, TA 500 NICE NICE SACT √ √
NHS ENGLAND/ TRUST GUIDELINES/ NICE/ TRUST GUIDELINES/ NICE/
CHEMOTHERAPY CANCER - (NOT SPECIFICALLY LISTED) CANCER EXCLUSION TRUST GUIDELINES/ NICE/ CDF POLICY SACT √
CDF CDF POLICY CDF POLICY
TRANSPLANT IMMUNOSUPPRESSION NEW PATIENTS ONLY UNTIL FORMAL PRODUCT WITH LOWEST
CICLOSPORIN NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √* √*
ONLY REPATRIATION AGREED PROCUREMENT COST TO BE USED
HYPERPARATHYROIDISM - DIALYSIS DRUGS FOR MINERAL BONE
CINACALCET NHS ENGLAND TA117 NICE NICE √
PATIENTS ONLY DISORDERS
CLOFARABINE CANCER CDF CANCER EXCLUSION CDF POLICY CDF CDF SACT √
DRUGS FOR MINERAL BONE
COLESTILAN ADULT RENAL DIALYSIS ONLY NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
DISORDERS
DARATUMUMAB CANCER CDF CANCER EXCLUSION CDF (TA 510) CDF CDF SACT √
RENAL DIALYSIS ONLY, INCLUDING VIA
PRODUCT WITH LOWEST
DARBEPOETIN DIALYSIS-INDUCED ANAEMIA NHS ENGLAND ERYTHROPOETINS OUTPATIENTS, AND ONLY AS PER NICE TRUST GUIDELINES TRUST GUIDELINES √
PROCUREMENT COST TO BE USED
CG114
RENAL DIALYSIS ONLY, INCLUDING VIA NICE NICE PRODUCT WITH LOWEST
EPOETIN (ALL VARIANTS) DIALYSIS-INDUCED ANAEMIA NHS ENGLAND ERYTHROPOETINS OUTPATIENTS, AND ONLY AS PER NICE TRUST GUIDELINES (RENAL TRUST GUIDELINES (RENAL PROCUREMENT COST TO BE USED √
CG114 USE ONLY) USE ONLY) (NICE CG114)
NHS ENGLAND/ NICE TA 423 NICE NICE
ERIBULIN CANCER CANCER EXCLUSION SACT √
CDF CDF POLICY CDF CDF
HYPERPARATHYROIDISM - DIALYSIS DRUGS FOR MINERAL BONE
ETELCALCETIDE NHS ENGLAND TA448 NICE NICE √ √
PATIENTS ONLY DISORDERS
FACTOR X (COAGADEX) HEREDITARY FACTOR X DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA429 NICE NICE
IBRUTINIB CANCER NHS ENGLAND/CDF PROTEIN KINASE INHIBITORS SACT √ √
CDF (TA491) CDF CDF
IDELALISIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE TA 359 NICE NICE SACT √
IPILIMUMAB CANCER NHS ENGLAND CANCER EXCLUSION TA268, TA319, 400 NICE NICE SACT √
DRUGS FOR MINERAL BONE
LANTHANUM ADULT RENAL DIALYSIS ONLY NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √
DISORDERS
LENVATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA498 NICE NICE SACT √ √
MESENCHYMAL STEM CELLS (E.G. ACUTE GVHD AND OTHER
NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PROCHYMAL®) INDICATIONS (BCSH)

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 11 23/03/2018


SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
TA481, TA482
TRANSPLANT IMMUNOSUPPRESSION PRODUCT WITH LOWEST
MYCOPHENOLATE MOFETIL NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
ONLY PROCUREMENT COST TO BE USED
REPATRIATION AGREED
TA481, TA482
TRANSPLANT IMMUNOSUPPRESSION PRODUCT WITH LOWEST
MYCOPHENOLIC ACID NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
ONLY PROCUREMENT COST TO BE USED
REPATRIATION AGREED
NELARABINE CANCER CDF CANCER EXCLUSION CDF POLICY CDF CDF SACT √
TA 384, 400, 417, 462 NICE NICE
NIVOLUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF (TA 483, TA 484, TA 490) CDF CDF
TA343 & 513 NICE NICE
OBINUTUZUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF (TA472) CDF CDF
OLAPARIB CANCER NHS ENGLAND CANCER EXCLUSION TA 381 NICE NICE SACT √
OLARATUMAB CANCER CDF CANCER EXCLUSION CDF (TA 465) CDF CDF SACT √ √
OSIMERTINIB CANCER CDF CANCER EXCLUSION CDF (TA 416) CDF CDF SACT √
PALBOCICLIB CANCER NHS ENGLAND CANCER EXCLUSION TA 495 NICE NICE SACT √ √
PANITUMUMAB CANCER NHS ENGLAND CANCER EXCLUSION TA439 NICE NICE SACT √ √

PANOBINOSTAT CANCER NHS ENGLAND CANCER EXCLUSION TA 380 NICE NICE SACT √

PEGASPARGASE CANCER NHS ENGLAND CANCER EXCLUSION TA 408 NICE NICE SACT √

PEGYLATED LIPOSOMAL NHS ENGLAND/ TA91 NICE NICE


CANCER CANCER EXCLUSION SACT √
DOXORUBICIN CDF CDF POLICY CDF CDF
NHS ENGLAND/ TA135, TA181, TA190, TA 402 NICE NICE
PEMETREXED CANCER CANCER EXCLUSION SACT √
CDF CDF CDF
PEPTIDE RECEPTOR
CANCER CDF NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RADIONUCLEOTIDE THERAPY

PERTUZUMAB CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 424 & 509 NICE NICE SACT √ √

PIXANTRONE CANCER NHS ENGLAND CANCER EXCLUSION TA306 NICE NICE SACT √

ENDOCRINOLOGY; NON-MALIGNANT
PROTEIN KINASE INHIBITORS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CONDITIONS
NHS ENGLAND/ NICE NICE
RADIUM-223 DICHLORIDE CANCER CANCER EXCLUSION NICE TA 376, TA 412 SACT √
CDF CDF CDF
NOT ROUTINELY COMMISSIONED -
RAMUCIRUMAB CANCER NHS ENGLAND CANCER EXCLUSION CDIFR CDIFR AS PER IFR APPROVAL √
TA 378
RIBOCICLIB CANCER NHS ENGLAND CANCER EXCLUSION TA 496 NICE NICE SACT √ √
DRUGS FOR MINERAL BONE
SEVELAMER ADULT RENAL DIALYSIS ONLY NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √
DISORDERS
TA481, TA482
TRANSPLANT IMMUNOSUPPRESSION PRODUCT WITH LOWEST
SIROLIMUS (RAPAMUNE) NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
ONLY PROCUREMENT COST TO BE USED
REPATRIATION AGREED
ADENOSINE DEAMINASE DEFICIENCY-
STRIMVELIS SEVERE COMBINED NHS ENGLAND ATMP HST7 NICE NICE NICE AUDIT √
IMMUNODEFICIENCY
CONTROL OF SERUM PHOSPHORUS
SUCROFERRIC OXYHDROXIDE NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
LEVELS IN DIALYSIS PATIENTS
TA481, TA482
TRANSPLANT IMMUNOSUPPRESSION PRODUCT WITH LOWEST
TACROLIMUS NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
ONLY PROCUREMENT COST TO BE USED
REPATRIATION AGREED
TALIMOGENE LAHERPAREPVEC CANCER NHS ENGLAND CANCER EXCLUSION TA 410 NICE NICE SACT √
ENDOCRINOLOGY; NON-MALIGNANT
TEMOZOLOMIDE NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CONDITIONS
TIVOZANIB CANCER CDF CANCER EXCLUSION TA 512 CDF CDF SACT √ √
TRABECTEDIN CANCER NHS ENGLAND ANTINEOPLASTIC DRUGS TA185 NICE NICE SACT √
TRAMETINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 396 NICE NICE SACT √ √
TRASTUZUMAB CANCER NHSE ENGLAND CANCER EXCLUSION TA 34, 107, 208 NICE NICE SACT √
TRASTUZUMAB EMTANSINE CANCER NHS ENGLAND CANCER EXCLUSION TA 458 NICE NICE SACT √ √
TRIFLURIDINE–TIPIRACIL CANCER NHS ENGLAND CANCER EXCLUSION TA 405 NICE NICE SACT √
VENETOCLAX CANCER CDF CANCER EXCLUSION CDF (TA 487) CDF CDF SACT √ √

* DRUG IS BEING REPATRIATED FROM PRIMARY TO SECONDARY CARE THEREFORE SUPPLY ROUTE MAY VARY AT PRESENT

** ROUTINELY COMMISSIONED IN COMBINATION WHEN DUAL THERAPY REQUIRED

*** ONLY WHEN PRESCRIBED IN AN ADULT SPECIALIST CENTRE


**** ONLY WHERE IT IS A RECOGNISED MS CENTRE WITH SPECIALIST NURSE SUPPORT

NEW LINES ADDED TO V13 LIST


CHANGES TO V12 17/18 LIST

ADDITIONAL NOTES:
1. WHERE THE FUNDED INDICATION IS FOR PAEDIATRIC USE THE CCG WILL BECOME THE RESPONSIBLE COMMISSIONER WHEN THE PATIENT IS TRANSFERRED TO THE ADULT SERVICE
2. CCGS ARE THE RESPONSIBLE COMMISSIONER FOR RITUXIMAB IN NON CANCEROUS HAEMOTOLOGICAL CONDITIONS (EG ITP) AND NON SPECIALIST AUTO-INFLAMMATORY CONDITIONS (EG RA)
3. ELTROMBOPAG AND ROMIPLOSTIM ARE THE RESPONSIBILTY OF CCGS REGARDLESS OF THE CAUSE OF THE THROMBOCYTOPENIA IN ADULTS (PAEDIATRICS ARE NHS
ENGLAND RESPONSIBILITY)
4. IT IS A MANDATED REQUIREMENT THAT ALL USE OF CHEMOTHERAPY IS RECORDED IN THE SACT DATABASE INCLUDING THOSE TREATMENTS FUNDED THROUGH THE CDF
5. USE IN VASCULAR DISEASE IS COMMISSIONED BY NHS ENGLAND WITHIN SPECIALIST CENTRES - CCG's ARE RESPONSIBLE FOR ALL OTHER INDICATIONS
6. NHS ENGLAND IS THE RESPONSIBLE COMMISSIONER WHEN SOMATROPIN ANALOGUES (GROWTH HORMONE) ARE PRESCRIBED IN SPECIALIST CENTRES FOR INDICATIONS FALLING OUTSIDE NICE GUIDANCE
7. NHS ENGLAND COMMISSIONS ARVS AS PER PUBLISHED POLICIES, FOR THE TREATMENT OF PEOPLE WITH DIAGNOSED HIV INFECTION AND FOR THOSE THOUGHT TO BE HIV POSITIVE (POST EXPOSURE PROPHYLAXIS). NHS ENGLAND DOES NOT ROUTINELY COMMISSION PRE-EXPOSURE PROPHYLAXIS AND THIS IS ONLY AVAILABLE TO
8.DRUGS APPROVED BY NICE FOR ADULT CONDITIONS WILL BE COMMISSIONED IN CHILDREN AT SPECIALISED PAEDIATRIC CENTRES IF THE PATIENT MEETS THE NICE CRITERIA AND THERE IS EVIDENCE TO SUGGEST THAT THE DRUG IS SAFE AND CLINICALLY APPROPRIATE TO USE IN CHILDREN. A PRESCRIBING POLICY IS IN
DEVELOPMENT TO CLARIFY THESE ARRANGEMENTS”. THIS WILL APPLY TO ANY DRUG WHERE WE HAVE STATED “AS PER ADULT TA” AS THE TA/ POLICY. A PRIOR APPROVAL SYSTEM WILL BE IMPLEMENTED ALONG SIDE THE POLICY.
9. CINACALCET FOR COMPLEX PRIMARY PARATHYROIDISM IS IN TARIFF

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 12 23/03/2018

Оценить